TY - JOUR AU - Nero, Camilla AU - Vizzielli, Giuseppe AU - Lorusso, Domenica AU - Cesari, Eleonora AU - Daniele, Gennaro AU - Loverro, Matteo AU - Scambia, Giovanni AU - Sette, Claudio PY - 2021 DA - 2021/03/31 TI - Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine JO - Journal of Experimental & Clinical Cancer Research SP - 116 VL - 40 IS - 1 AB - High grade serous ovarian cancer (HGSOC) is among the deadliest human cancers and its prognosis remains extremely poor. Tumor heterogeneity and rapid acquisition of resistance to conventional chemotherapeutic approaches strongly contribute to poor outcome of patients. The clinical landscape of HGSOC has been radically transformed since the advent of targeted therapies in the last decade. Nevertheless, the lack of predictive biomarkers informing on the differential clinical benefit in select subgroups, and allowing patient-centric approaches, currently limits the efficacy of these novel therapies. Thus, rational selection of the best possible treatment for each patient represents a clinical priority in order to improve outcome, while limiting undesirable effects. SN - 1756-9966 UR - https://doi.org/10.1186/s13046-021-01917-7 DO - 10.1186/s13046-021-01917-7 ID - Nero2021 ER -